Free Preview — Investor scores & financials for TMO. Sign up for full buy targets.
Start Free

Is Thermo Fisher Scientific Inc. (TMO) Undervalued? Valuation & Fair Price

At $651.45, 4 of the 4 frameworks would pass on Thermo Fisher Scientific Inc. today — Warren Buffett, Benjamin Graham, Peter Lynch, and Phil Town (Rule #1) rate it Avoid. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.

TM

Thermo Fisher Scientific Inc.

TMO

Healthcare · Medical - Diagnostics & Research · NYSE

$651.45

P/E 32.4×

CEO

Marc N. Casper

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.

Investor scorecard

How the four investors rate Thermo Fisher Scientific Inc.

4 of 4 frameworks urge caution

Warren Buffett
33%Avoid
Benjamin Graham
29%Avoid
Peter Lynch
39%Avoid
Phil Town (Rule #1)
27%Avoid

Investor model analysis

Details locked

At $651.45, 4 of 4 frameworks say Avoid

Business Quality32/100

Intrinsic Value (DCF)

Warren Buffett's valuation model · select an investor above to switch

Intrinsic Value

Locked — upgrade to view

Buy Below

Locked — upgrade to view

Strong Buy

Locked — upgrade to view

Margin of Safety

Locked — upgrade to view

Unlock buy targets with a free account

Get started

Create a free account to see buy targets, full checklists & risk analysis Get started

Insider & congress activity

Are insiders buying TMO?

Over recent SEC Form 4 filings, TMO insiders bought $0 and sold $42.0M of stock across 55 open-market trades. Insiders sell for many reasons, but they buy for one.

Bought $0Sold $42.0M
Recent open-market insider trades for TMO
InsiderActionSharesValueDate
Pettiti GianlucaPresident & COOSell3,733$2.3MAug 31, 2026
CASPER MARC NChairman & CEOSell101$63KAug 24, 2026
CASPER MARC NChairman & CEOSell33$21KAug 24, 2026
CASPER MARC NChairman & CEOSell79$50KAug 24, 2026
CASPER MARC NChairman & CEOSell62$39KAug 24, 2026

Members of Congress have also reported 50 trades in TMO. See the full insider & congress timeline.

Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.

See the interactive insider chart & every trade

Scenario analysis

Bear, base & bull

Three growth assumptions, three fair values — and where today's price lands

What's working

Key strengths

Identified by Buffett framework analysis

Gross Margin

Net Profit Margin

Positive Free Cash Flow

Risk factors & concerns — free account

Unlock

Company financials

5-Year Financials

Income statement highlights — annual, USD

Metric20252024202320222021
Revenue$44.6B
$42.9B
$42.9B
$44.9B
$39.2B
Rev. Growth+3.9%+0.1%-4.6%+14.5%—
Net Income$6.7B$6.3B$6.0B$7.0B$7.7B
Net Margin15.1%14.8%14.0%15.5%19.7%
EPS (Diluted)$17.77$16.58$15.53$17.73$19.61
Free Cash FlowLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to view

Full analysis included

See the complete picture for TMO

Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.

Buy & sell targetsFull checklistRisk breakdown

Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo

More Healthcare stocks

Educational Use Only · Not Financial Advice

Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.